Inyx, Accentia to promote MD Turbo for dose inhalers

By Elaine Rigoli

Tampa, Fla., April 12 - Exaeris, Inc., a wholly owned subsidiary of Inyx, Inc. and Teamm Pharmaceuticals, Inc., the specialty pharmaceutical division of Accentia BioPharmaceuticals, Inc., have finalized a co-promotion agreement to co-market MD Turbo, a breath-activated, dose-counting companion to meter dose inhalers.

MD Turbo will be available by prescription in the United States later this quarter, according to a news release.

MD Turbo contains an electronic dose counter to help patients improve medication compliance by tracking the number of doses remaining before a refill is required.

Tampa, Fla.-based Accentia is a biopharmaceutical company focused on the development of late-stage clinical products in the therapeutic areas of respiratory disease and oncology.

Inyx, based in Manati, Puerto Rico, is a specialty pharmaceutical company with products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.